한국비엔씨
2,475KRWMarket close of 10/27 (Tue)
Flat 0.00%0KRWMarket close of 10/27 (Tue)
Preliminary value — replaced once official KRX data for the same date is publishedClose of 10/28 (Wed)2,485KRWUp +0.40%
Preliminary · replaced once official KRX data for the same date is published
- Open
- 2,485
- High
- 2,560
- Low
- 2,455
- Day range
- Day range low 2,455 high 2,560, open 2,485, close 2,475, previous close 2,475
- Volume
- 46×10K shares
- 1.1B KRW 0.10× the 20-session average
Market close of 10/27 (Tue)
Free · no sign-inSource from 2021-05-17
Points to check
- Earningsto check-3.6B KRWOperating income over the last four quarters -3.6B KRW (loss)
- Daily movenot verifiedOnly 19 daily bars to compare, so not verified
- Trading valuenot verifiedNot enough 20-session trading value data, so not verified
The other 2
- Recent filingsnot verified
- Foreign & institutionalnot verified
With 19 trading days, the 1-year position isn't calculated · First data date 9/29 (Tue)
See the full check report
Quarterly results · Q1 2026
- Revenue20.7B KRW
- vs. year ago
- -18.4%
- vs. prior quarter
- -12.1%
- Operating income-1.5B KRW
- vs. year ago
- Turned to loss
- vs. prior quarter
- Still a loss
- Operating margin-7.1%
- vs. year ago
- -22.1 pp
- vs. prior quarter
- +2.9 pp
Quarterly operating income trend
As of the latest official close · 2026-10-27Valuation filing date · 2026-05-15Same sector · 제약
Down -2.22%· 88 of 168 stocks up, preferred shares excluded · trading value 553.0B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 삼성바이오로직스 | Close over the last 20 sessions +0.6% | Down -5.37% | 124.5B KRW |
| 셀트리온 | Close over the last 20 sessions +6.3% | Down -0.74% | 82.4B KRW |
| 지투지바이오 | Close over the last 20 sessions +22.2% | Down -13.38% | 46.9B KRW |
| 한미약품 | Close over the last 20 sessions -32.6% | Down -0.57% | 25.5B KRW |
| 에스티팜 | Close over the last 20 sessions -11.9% | Down -9.15% | 21.4B KRW |
Schedule
- Next data 10/29 (Thu) after 08:50
Related news
Tables, financials, investor flows and filing history are in the Detailed view.
Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 82% of trading value, about 92% of market capitalisation. Coverage status →
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.